Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders

About this update from Alcon Ag

[{"type":"text","content":"STAAR Special Meeting of Stockholders Adjourned to January 6, 2026","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"LAKE FOREST, Calif., December 19, 2025--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the "Special Meeting"). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to January 6, 2026 at 8:30 a.m. Eastern Time. The record date for STAAR stockholders eligible to vote at the Special Meeting remains the close of business on October 24, 2025.","length":695,"tagName":"p"},{"type":"text","content":"Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:","length":125,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"For stockholders: +1 877-750-8233 (toll-free from the U.S. and Canada) or +1 412-232-3651 (from other countries)","length":112,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"For banks and brokerage firms: +1 212-750-5833","length":46,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":158,"olType":false},{"type":"text","content":"About STAAR Surgical","length":20,"tagName":"p"},{"type":"text","content":"STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, dev...

More updates from Alcon Ag